253 related articles for article (PubMed ID: 38250045)
21. Refining the delivery and therapeutic efficacy of cetuximab using focused ultrasound in a mouse model of glioblastoma: An
Porret E; Kereselidze D; Dauba A; Schweitzer-Chaput A; Jegot B; Selingue E; Tournier N; Larrat B; Novell A; Truillet C
Eur J Pharm Biopharm; 2023 Jan; 182():141-151. PubMed ID: 36529256
[TBL] [Abstract][Full Text] [Related]
22. Intratumoral IL-12 delivery via mesenchymal stem cells combined with PD-1 blockade leads to long-term antitumor immunity in a mouse glioblastoma model.
Park J; Park SA; Kim YS; Kim D; Shin S; Lee SH; Jeun SS; Chung YJ; Ahn S
Biomed Pharmacother; 2024 Apr; 173():115790. PubMed ID: 38431436
[TBL] [Abstract][Full Text] [Related]
23. CD8
Seo JW; Tavaré R; Mahakian LM; Silvestrini MT; Tam S; Ingham ES; Salazar FB; Borowsky AD; Wu AM; Ferrara KW
Clin Cancer Res; 2018 Oct; 24(20):4976-4987. PubMed ID: 29967252
[No Abstract] [Full Text] [Related]
24. Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine.
Liu CJ; Schaettler M; Blaha DT; Bowman-Kirigin JA; Kobayashi DK; Livingstone AJ; Bender D; Miller CA; Kranz DM; Johanns TM; Dunn GP
Neuro Oncol; 2020 Sep; 22(9):1276-1288. PubMed ID: 32133512
[TBL] [Abstract][Full Text] [Related]
25. Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy.
Panagioti E; Kurokawa C; Viker K; Ammayappan A; Anderson SK; Sotiriou S; Chatzopoulos K; Ayasoufi K; Johnson AJ; Iankov ID; Galanis E
J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 34196308
[TBL] [Abstract][Full Text] [Related]
26. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
[TBL] [Abstract][Full Text] [Related]
27. Whole-body PET Imaging of T-cell Response to Glioblastoma.
Nobashi TW; Mayer AT; Xiao Z; Chan CT; Chaney AM; James ML; Gambhir SS
Clin Cancer Res; 2021 Dec; 27(23):6445-6456. PubMed ID: 34548318
[TBL] [Abstract][Full Text] [Related]
28. Monitoring CD8a
Kristensen LK; Christensen C; Alfsen MZ; Cold S; Nielsen CH; Kjaer A
Mol Imaging Biol; 2020 Aug; 22(4):1021-1030. PubMed ID: 32086762
[TBL] [Abstract][Full Text] [Related]
29. Efficient PD-L1 imaging of murine glioblastoma with FUS-aided immunoPET by leveraging FcRn-antibody interaction.
Chevaleyre C; Novell A; Tournier N; Dauba A; Dubois S; Kereselidze D; Selingue E; Jego B; Maillère B; Larrat B; Nozach H; Truillet C
Theranostics; 2023; 13(15):5584-5596. PubMed ID: 37908736
[No Abstract] [Full Text] [Related]
30. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.
Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558
[TBL] [Abstract][Full Text] [Related]
31. Oncolytic adenovirus decreases the proportion of TIM-3
Liikanen I; Basnet S; Quixabeira DCA; Taipale K; Hemminki O; Oksanen M; Kankainen M; Juhila J; Kanerva A; Joensuu T; Tähtinen S; Hemminki A
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193929
[TBL] [Abstract][Full Text] [Related]
32. Local and distant response to intratumoral immunotherapy assessed by immunoPET in mice.
Meyblum L; Chevaleyre C; Susini S; Jego B; Deschamps F; Kereselidze D; Bonnet B; Marabelle A; de Baere T; Lebon V; Tselikas L; Truillet C
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37949616
[TBL] [Abstract][Full Text] [Related]
33. ImmunoPET imaging-based pharmacokinetic profiles of an antibody and its Fab targeting endothelin A receptors on glioblastoma stem cells in a preclinical orthotopic model.
Hautiere M; Vivier D; Pineau D; Denis C; Kereselidze D; Herbet A; Costa N; Goncalves V; Selingue E; Larrat B; Hugnot JP; Denat F; Boquet D; Truillet C
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3192-3201. PubMed ID: 37280303
[TBL] [Abstract][Full Text] [Related]
34. Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy.
Duebgen M; Martinez-Quintanilla J; Tamura K; Hingtgen S; Redjal N; Wakimoto H; Shah K
J Natl Cancer Inst; 2014 Jun; 106(6):dju090. PubMed ID: 24838834
[TBL] [Abstract][Full Text] [Related]
35. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.
Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY
Front Immunol; 2018; 9():727. PubMed ID: 29910795
[TBL] [Abstract][Full Text] [Related]
36. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
[TBL] [Abstract][Full Text] [Related]
37. Recruiting T-Cells toward the Brain for Enhanced Glioblastoma Immunotherapeutic Efficacy by Co-Delivery of Cytokines and Immune Checkpoint Antibodies with Macrophage-Membrane-Camouflaged Nanovesicles.
Xu X; Zhang Z; Du J; Xue Y; Chen X; Zhang J; Yang X; Chang D; Xie J; Ju S
Adv Mater; 2023 Jun; 35(25):e2209785. PubMed ID: 37101060
[TBL] [Abstract][Full Text] [Related]
38. Removal of Fc Glycans from [
White JM; Keinänen OM; Cook BE; Zeglis BM; Gibson HM; Viola NT
Mol Pharm; 2020 Jun; 17(6):2099-2108. PubMed ID: 32330387
[TBL] [Abstract][Full Text] [Related]
39. Implications of immune cells in oncolytic herpes simplex virotherapy for glioma.
Otani Y; Yoo JY; Shimizu T; Kurozumi K; Date I; Kaur B
Brain Tumor Pathol; 2022 Apr; 39(2):57-64. PubMed ID: 35384530
[TBL] [Abstract][Full Text] [Related]
40. Combination immunotherapy strategies for glioblastoma.
Chan HY; Choi J; Jackson C; Lim M
J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
